APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Traditional Alzheimer's disease (AD) research focused on brain pathology and autosomal dominant familial AD genetics.
• Despite decades of research, therapeutic targets identified through these approaches have not yielded clinically significant results.
• This necessitates complementary strategies and novel therapeutic targets for AD.

Purpose of the Study:

• To address the understudied role of apolipoprotein E4 (APOE ε4) in sporadic AD.
• To review emerging therapeutic approaches targeting apoE4 for Alzheimer's disease.
• To highlight the significance of APOE ε4 as a prevalent genetic risk factor.

Main Methods:

• Review of existing literature on AD pathology and genetics.
• Analysis of the role of APOE ε4 in sporadic AD.
• Identification and discussion of novel therapeutic strategies targeting apoE4.

Main Results:

• APOE ε4 is the most common genetic risk factor for sporadic AD, present in over half of patients.
• Despite its prevalence, APOE ε4 and apoE4 protein have been historically understudied.
• Newly developed therapeutic approaches targeting apoE4 show promise for future AD studies.

Conclusions:

• Complementary therapeutic approaches are crucial for effective AD treatment.
• Targeting apoE4 represents a promising avenue for developing new Alzheimer's disease therapies.
• Further research into apoE4's role is essential for advancing AD treatment strategies.